The identification of those genes that are frequently mutated in malignancies is essential for a full understanding of the molecular pathogenesis of these disorders, and often for the provision of markers for the study of disease progression. Recently, mutation of the ASXL1 (additional sex combs 1) gene has been reported in 4 out of 35 patients (11%) with myelodysplastic syndromes (MDS) and in 17 out of 39 patients (43%) with chronic myelomonocytic leukemia (CMML), a disease classified as MDS/myeloproliferative disorder. 1 The mutations were all found in exon 12 of the gene and are predicted to lead to the truncation of the C-terminus of the protein, which contains a PHD finger. 1 The PHD finger is a structural motif found in nuclear proteins involved in chromatin modifications. The function of the human ASXL1 protein is poorly understood, but there is some evidence to suggest that it may represent a component of DNA-and/or histone-modifying complexes.
2 ASXL1 belongs to a family of three members that encode polycomb and mixed-lineage leukemia/trithorax chromatin modifier complexes.
2 Most recently, mutations of ASXL1 have been reported in 5 out of 64 (approximately 8%) patients with the myeloproliferative disorders essential thrombocythemia and primary myelofibrosis, and in 11 out of 63 (17%) patients with acute myeloid leukemia (AML). 3, 4 These data suggest that ASXL1 represents a new tumor suppressor gene, the inactivation of which may have an important role in the molecular pathogenesis of malignant myeloid disorders.
We have screened ASXL1 for mutations in a large group of patients with MDS, CMML and AML, in order to determine their frequency in these malignant myeloid disorders and to determine any association with specific MDS subtypes, karyotypic groups and disease progression. Moreover, we have determined the effect of these mutations on global gene expression patterns and gene pathways.
A total of 300 patients with MDS, AML or CMML and 111 healthy controls were included in this study. The study was approved by the ethics committees of the institutes involved (Oxford C00.196, Bournemouth 9991/03/E, Duisburg 2283/03, Stockholm 410/03, Pavia 26264/2002, PamplonaFapproval by the Investigational Review Boards at the University of Navarra) and informed consent was obtained. Genomic DNA was isolated from patient bone marrow or peripheral blood samples by phenol/chloroform extraction using standard methods and evaluated for quality and concentration using an ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
All previously reported mutations of ASXL1 in hematological malignancies were found exclusively in exon 12 of the gene.
1,3
Sequences spanning exon 12 of the ASXL1 gene were amplified by PCR from the DNA of 300 patient samples and 111 normal controls. Primers and amplification conditions were as previously published.
1 PCR products were purified and directly sequenced using the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 Genetic analyzer. Sequence data were analyzed using Mutation Surveyor V3.25 (Softgenetics, State College, PA, USA).
ASXL1 mutations were observed in 62 out of the 300 patients (21%; Table 1 ). ASXL1 mutations were found in 5 out of 79 MDS patients with refractory anemia (RA; 6%), in 17 out of 55 patients with either refractory anemia with excess blasts 1 (RAEB-1) or RAEB-2 (31%), and in 17 out of 67 patients with AML (25%; Table 1 ). Thus, the mutation frequency is relatively high in late MDS and AML, with a lower frequency across the spectrum of early MDS (Table 1) . Examining the mutation frequency by karyotype shows that the mutation is common in Table 1 ASXL1 mutations in our series of patients with malignant myeloid disorders
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB-1, refractory anemia with excess blasts 1; RAEB-2, refractory anemia with excess blasts 2; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts. The frequency of ASXL1 mutations is shown in each disease subtype and in different karyotypic groups.
Letters to the Editor the normal karyotype group (especially in AML post MDS) and the del(7q)/monosomy 7 group, occurring in 40% of all cases, respectively (Table 1 ). In contrast, the mutation is uncommon in the del(5q)/monosomy 5 group (Table 1) . To investigate whether the mutations were acquired, we analyzed germline DNA from T cells of seven cases. In all cases examined, the ASXL1 mutations were restricted to the non-lymphoid cells, indicating that they were acquired. The majority of the mutations identified in this study were heterozygous frameshift mutations caused by deletion or duplication of a nucleotide. The most common mutation was 1934dupG;Gly646TrpfsX12, which accounted for 55% of all mutations. Another three mutations were identified in more than one patient; these were 1900-1922del;E635RfsX15 (8% of mutations), 1872_1894het_del;E630RfsX14 (5%) and Letters to the Editor 1925het_insA;G643RfsX13 (5%). Indeed, we have found that the majority of mutations are localized to one particular region within exon 12, around the Gly-rich domain (amino acids 642-685) ( Figure 1a) . Interestingly, 97% of the mutations that lead to a truncated protein are located before the C-terminal nuclear receptor box, which is predicted to interact with the retinoic acid receptor.
5
None of the previously mentioned mutations were present in the 111 healthy controls. In our control group we found four non-synonymous changes that were not previously reported. In addition to these, we found seven different single base changes in our patient group, five of which were missense changes that could theoretically be polymorphisms and are hence excluded from Table 1 .
Therefore, the mutation of ASXL1 has two features, which should enable it to be used as a molecular marker for studies on minimal residual disease and disease progression. These are (1) its high frequency (and in particular its high frequency in normal karyotype MDS/AML) and (2) the fact that many of the mutations are frameshifts, which provide good targets for sensitive detection assays.
SNP array analysis was performed using Affymetrix Genechip Mapping 50K HindIII arrays (Affymetrix, Santa Clara, CA, USA), as previously described, 6 on approximately half (89 of 182) of the MDS patients included in this study, and two patients with mutation of ASXL1 were shown to have a deletion mapping to 20q encompassing the ASXL1 gene (data not shown). Intriguingly, the ASXL1 gene maps close to the critically deleted region identified on 20q in a range of myeloid malignancies.
7
Gene expression profiling was performed on CD34 þ cells obtained from a subset of the MDS patients (n ¼ 29) and the CMML patients (n ¼ 7) with and without mutation of ASXL1. Gene expression profiling was performed using Affymetrix HG U133 Plus 2.0 arrays as previously described.
8 Affymetrix CEL files were pre-processed using Robust MultiChip Analysis and data analysis was performed using GeneSpring 7.3.1 (Agilent Technologies, Santa Clara, CA, USA). The differentially expressed genes (30 genes, t-test Po0.05) between the 11 cases with mutation and the 25 cases without mutation of ASXL1 were used for hierarchical clustering and a good separation between cases with and those without a mutation of ASXL1 was obtained (Figure 1b) , suggesting that patients with mutation of ASXL1 have a different disease pathophysiology. The Ingenuity Pathway Analysis 7.5 software (Ingenuity Systems, Redwood City, CA, USA) was used to perform pathway analysis on the differentially expressed genes between patients with mutation of ASXL1 and controls (849 genes, t-test Po0.05), and this showed that the most significantly deregulated pathway in patients with a mutation of ASXL1 was the retinoic acid receptor (RAR) activation (Table 2 ). Several genes in this pathway, including RXRA, PRKCA, PRKCD, CSNK2A2 and ADCY1, showed upregulation in patients with mutation of ASXL1. Intriguingly, ASXL1 has been suggested to function either as a co-activator or as a co-repressor for retinoid receptors RAR and retinoid X receptor (RXR) in a cell type-specific manner.
5,9 The RAR activation pathway was not among the top 50 deregulated pathways in patients without a mutation of ASXL1.
The high frequency of ASXL1 mutations in CMML/MDS/AML makes it a very significant mutation. Moreover, our study shows that ASXL1 mutations are the commonest known mutations in advanced MDS, suggesting their important role in disease progression.
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